Trials / Unknown
UnknownNCT04752865
Effects of Cytotoxic Chemotherapy and PARP Inhibition on the Genomic Contexture of Ovarian Cancer
- Status
- Unknown
- Phase
- —
- Study type
- Observational
- Enrollment
- 50 (estimated)
- Sponsor
- Hellenic Cooperative Oncology Group · Academic / Other
- Sex
- Female
- Age
- 18 Years – 80 Years
- Healthy volunteers
- Not accepted
Summary
EFFECTS OF CYTOTOXIC CHEMOTHERAPY AND PARP INHIBITION ON THE GENOMIC CONTEXTURE OF OVARIAN CANCER: TR\_NACT\_OV/17 In order to approach the above open questions, ultimately aiming in understanding the effects of cancer drugs on tumor biology and hence in selecting the proper drugs for the patients in the context of Precision Medicine, the objective of this study is to study the genomic characteristics of ovarian tumors before and after treatment with classic neoadjuvant chemotherapy (NACT) and with the more recently approved PARP inhibitor olaparib.
Conditions
Timeline
- Start date
- 2018-02-09
- Primary completion
- 2023-12-01
- Completion
- 2024-06-01
- First posted
- 2021-02-12
- Last updated
- 2023-03-01
Locations
1 site across 1 country: Greece
Source: ClinicalTrials.gov record NCT04752865. Inclusion in this directory is not an endorsement.